2,944 results on '"BELIMUMAB"'
Search Results
2. A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)
- Published
- 2024
3. Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
- Published
- 2024
4. Belimumab in Autoimmune Hepatitis (BELief)
- Author
-
GlaxoSmithKline
- Published
- 2024
5. Belimumab With Rituximab for Primary Membranous Nephropathy (REBOOT)
- Author
-
Immune Tolerance Network (ITN), GlaxoSmithKline, PPD, and Rho Federal Systems Division, Inc.
- Published
- 2024
6. Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
- Published
- 2024
7. Belimumab in SLE Synovial Inflammation and Lymph Nodes
- Author
-
GlaxoSmithKline and Sander Tas, Prof. dr.
- Published
- 2024
8. Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
- Author
-
GlaxoSmithKline and American Cancer Society, Inc.
- Published
- 2024
9. Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Author
-
GlaxoSmithKline
- Published
- 2024
10. Trial of Belimumab in Early Lupus
- Author
-
GlaxoSmithKline and Cynthia Aranow, MD, Professor
- Published
- 2024
11. Belimumab in Idiopathic Inflammatory Myositis (BIM)
- Author
-
GlaxoSmithKline and Galina Marder, MD, Director, Inflammatory Muscle Disease and Vasculitis Center
- Published
- 2024
12. A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)
- Published
- 2024
13. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
- Author
-
Arends, Eline J, Zlei, Mihaela, Tipton, Christopher M, Cotic, Jasna, Osmani, Zgjim, Bie, Fenna J de, Kamerling, Sylvia W A, Maurik, Andre van, Dimelow, Richard, Gregan, Yun Irene, Fox, Norma Lynn, Rabelink, Ton J, Roth, David A, Sanz, Ignacio, Dongen, Jacques J M van, Kooten, Cees van, and Teng, Y K Onno
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *FLOW cytometry , *IMMUNOSUPPRESSIVE agents , *REGULATORY B cells , *SYSTEMIC lupus erythematosus , *IMMUNOLOGIC memory , *META-analysis , *RETROSPECTIVE studies , *CELL motility , *LYMPHOCYTES , *BIOLOGICAL products , *DESCRIPTIVE statistics , *BELIMUMAB , *DRUG efficacy , *GENE expression profiling , *B cells , *SEQUENCE analysis - Abstract
Objectives Autoreactive memory B cells (MBCs) contribute to chronic and progressive courses in autoimmune diseases like SLE. The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and LN, is generally attributed to depletion of activated naïve B cells and inhibition of B-cell activation. BEL's effect on MBCs is currently unexplained. We performed an in-depth cellular and transcriptomic analysis of BEL's impact on the blood MBC compartment in patients with SLE. Methods A retrospective meta-analysis was conducted, pooling flow cytometry data from four randomized trials involving 1245 patients with SLE treated with intravenous BEL or placebo. Then, extensive MBC phenotyping was performed using high-sensitivity flow cytometry in patients with mild/moderate SLE and severe SLE/LN treated with subcutaneous BEL. Finally, transcriptomic characterization of surging MBCs was performed by single-cell RNA sequencing. Results In BEL-treated patients, a significant increase in circulating MBCs, in a broad range of MBC subsets, was established at week 2, gradually returning to baseline by week 52. The increase was most prominent in patients with higher SLE disease activity, serologically active patients and patients aged ≤18 years. MBCs had a non-proliferating phenotype with a prominent decrease in activation status and downregulation of numerous migration genes. Conclusion Upon BEL initiation, an increase of MBCs was firmly established. In the small cohort investigated, circulating MBCs were de-activated, non-proliferative and demonstrated characteristics of disrupted lymphocyte trafficking, expanding on our understanding of the therapeutic mechanism of B-cell-activating factor inhibition by BEL. Trial registration ClinicalTrials.gov, http://clinicaltrials.gov , NCT00071487, NCT00410384, NCT01632241, NCT01649765, NCT03312907, NCT03747159. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
- Author
-
Li, Huarong, Chen, Chaoying, Yang, Hongxian, and Tu, Juan
- Subjects
- *
SYSTEMIC lupus erythematosus , *LUPUS nephritis , *GLOMERULAR filtration rate , *BELIMUMAB , *HEMATURIA - Abstract
The purpose of this study is to evaluate the efficacy and safety of belimumab combined with the standard regimen in treating children with active lupus nephritis. This single-center, retrospective cohort study used clinical data of children with newly active lupus nephritis hospitalized in the Department of Nephrology between December 2004 and February 2023. Patients were divided into a belimumab or traditional treatment group according to whether or not they received belimumab. Renal remission and recurrence rates and glucocorticoid dose were compared between groups. Forty-seven children (median age 11 years) were enrolled, including 30 and 17 children in the traditional treatment and belimumab groups, respectively. The Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) score of children in the belimumab group (23.59 ± 7.78) was higher than that in the traditional treatment group (19.13 ± 6.10) (P = 0.035). The two groups showed no significant difference in the frequency of pyuria, gross hematuria, and the levels of 24-h proteinuria and estimated glomerular filtration rate. The complement C3/C4 in the belimumab group recovered faster than that in the traditional treatment group (P < 0.05). There were no between-group differences in the complete renal remission rate at 6 or 12 months (P = 0.442, P = 0.759). There were no between-group differences in 1-year recurrence rate (P = 0.303). Furthermore, 6 and 12 months after treatment, glucocorticoid doses were lower in the belimumab than the traditional treatment group (17.87 ± 6.96 mg/d vs. 27.33 ± 8.40 mg/d, P = 0.000; 10.00 (5.3) mg/d vs. 13.75 (10.0) mg/d, P = 0.007), respectively. Conclusion: With an equivalent renal remission rate, belimumab combined with the standard traditional regimen might promote the tapering of glucocorticoids, and the incidence of adverse events is low. What is known: • Belimumab is documented as an adjunctive treatment with systemic lupus erythematosus (c-SLE) LN with efficacy. • Due to the paucity of studies, its effects and side effects in children with LN remain unclear. What is new: • This single-center, retrospective cohort study evaluated the efficacy and safety of belimumab combined with the standard regimen in treating children with proliferative LN. • Belimumab combined with the standard traditional treatment might promote the tapering of glucocorticoids, while exhibiting a low occurrence of adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: A retrospective observational study.
- Author
-
Liu, Yu, Li, Yongzhen, Shen, Tian, Zhang, Huiming, Luo, Shuangyan, Zhang, Qing, Dang, Xiqiang, Li, Xiaoyan, and Long, Hai
- Published
- 2024
- Full Text
- View/download PDF
16. Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study.
- Author
-
Rubin, Bernard, Chen, Yan, Worley, Karen, Rabideau, Brendan, Wu, Benson, Chang, Rose, and DerSarkissian, Maral
- Subjects
- *
SYSTEMIC lupus erythematosus , *BELIMUMAB , *TREATMENT effectiveness - Abstract
Introduction: Patients with systemic lupus erythematosus (SLE) have variable treatment pathways, including antimalarials, glucocorticoids, immunosuppressants, and/or biologics. This study describes differences in clinical outcomes when initiating belimumab (BEL) before and after immunosuppressant use. Methods: This real-world, retrospective cohort study (GSK Study 217536) used de-identified administrative claims data from January 2015 to December 2022 in the Komodo Health Database. Adults with moderate/severe SLE initiating BEL (index date) were identified from January 2017 to May 2022, allowing a ≥ 24-month baseline period. Patients were stratified into those initiating BEL before immunosuppressant use (no immunosuppressant use within 24 months before index) and those initiating BEL after immunosuppressant use (one immunosuppressant used within 24 months before index). Oral glucocorticoid (OGC) use, SLE flares, new organ damage, and all-cause healthcare resource utilization (HCRU) were analyzed descriptively over a 24-month follow-up. Results: Baseline SLE severity was similar for patients initiating BEL before (n = 2295) versus after (n = 4114) immunosuppressant use (moderate, 83.1% vs 79.0%; severe, 16.8% vs 21.0%). Patients initiating BEL before versus after immunosuppressant use had lower SLE flare rates and OGC use. Post-index, patients initiating BEL before versus after immunosuppressant use discontinued their OGC sooner (moderate baseline SLE, 4.5 vs 8.9 months; severe baseline SLE, 6.2 vs 11.6 months). Patients initiating BEL before versus after immunosuppressant use had lower SLE flare rates per person-year at all time points (especially severe flare rates in patients with severe baseline SLE, 0.70 vs 1.48 through 24 months post-index). Median time to new organ damage occurrence was longer in patients initiating BEL before versus after immunosuppressant use (moderate baseline SLE, 32.1 vs 26.7 months; severe baseline SLE, 22.7 vs 21.6 months). All-cause HCRU was similar between cohorts. Conclusions: These results suggest that patients initiating BEL before versus after immunosuppressant use had more favorable outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Effects of belimumab on the lipid profile in systemic lupus erythematosus patients: an observational study.
- Author
-
Liang, Di, Huang, Shimei, and Ding, Rui
- Subjects
- *
BELIMUMAB , *LDL cholesterol , *SYSTEMIC lupus erythematosus , *APOLIPOPROTEIN A , *GENERALIZED estimating equations , *COMPLEMENT (Immunology) , *DYSLIPIDEMIA - Abstract
This study is asked to investigate the effects of belimumab on the lipid profile in systemic lupus erythematosus (SLE) patients. Forty-one SLE patients who received at least 6 months of belimumab treatment were retrospectively analyzed. The control group consisted of 56 age- and sex-matched lupus patients not treated with belimumab. The changes in lipid profile after a 6-month treatment were compared between the two groups. Generalized estimating equation (GEE) analyses were performed to examine lipid levels longitudinally during the period and the effect of clinical response variables and medication on the lipid profile in the belimumab group. In the belimumab group, high-density lipoprotein (HDL) cholesterol levels increased significantly after the 6-month treatment (P = 0.02). After 1 month, HDL, apolipoprotein A-I (apoA-I) significantly increased by 13.8 and 11.4%, compared with baseline, respectively. After 3 months, HDL and apoA-I increased by 9.0 and 7.1%, respectively. After 6 months, HDL increased by 7.6% compared with baseline. Total cholesterol, triglycerides, low-density lipoprotein cholesterol, and apolipoprotein B did not change significantly over the course of treatment. GEE analyses indicated a significant association between HDL and disease activity indexes, such as IgG, anti-dsDNA, and complement C3. Subgroup analysis revealed significant changes in HDL only in patients who had achieved a ≥ 4-point reduction in SLEDAI-2 K after 6 months of belimumab treatment. Belimumab treatment may result in a long-term increase in HDL level in SLE patients by improving control of lupus activity. This might have beneficial effects on controlling cardiovascular risk in lupus patients. Key Points • Treatment with belimumab resulted in a significant and sustained increase in the HDL levels in SLE patients. • Significant changes in HDL were observed in lupus patients treated with belimumab who had a better clinical response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Belimumab-induced periungual pyogenic granulomas: A case report.
- Author
-
Chighizola, Cecilia Beatrice, Suardi, Ilaria, Marino, Achille, Gattinara, Maurizio, Costi, Stefania, Cattaneo, Angelo, Gerosa, Maria, and Caporali, Roberto
- Subjects
- *
SYSTEMIC lupus erythematosus , *BELIMUMAB , *SYMPTOMS , *DRUG side effects , *MONOCLONAL antibodies - Abstract
Pyogenic granuloma (PG) is a benign vascular neoformation, presenting as a painful red nodule on the skin, mucosa or nail apparatus. It is usually related to local complications such as bleedings and superinfections. The etiology of PG remains still unclear, and several triggers can lead to its formation. In case of multiple lesions, systemic conditions and drugs remain the main causes. Antineoplastic treatments, retinoids, antiretrovirals, hormones and anticonvulsants are frequently implicated in PG formation. In literature, PG has been rarely described in the course of biological treatment due to rheumatological disease. The present case report describes the development of polydactolous PGs in a 21-year-old woman with juvenile systemic lupus erythematosus (jSLE) during treatment with belimumab, a monoclonal antibody directed against BlyS. The clinical presentation, in particular the timing and the multiplicity of the lesions, and the improvement after belimumab discontinuation allowed us to consider PG as drug-induced. This case highlights the importance of considering PG as a potential complication of rheumatologic treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Evaluation of intra‐ and inter‐individual variations in plasma belimumab concentrations in adult patients with systemic lupus erythematosus.
- Author
-
Yoshijima, Chisato, Suzuki, Yosuke, Tanaka, Ryota, Ono, Hiroyuki, Oda, Ayako, Ozaki, Takashi, Shibata, Hirotaka, Itoh, Hiroki, and Ohno, Keiko
- Subjects
- *
SYSTEMIC lupus erythematosus , *LIQUID chromatography-mass spectrometry , *BELIMUMAB - Abstract
In this study, plasma belimumab concentrations were measured over the course of treatment in systemic lupus erythematosus (SLE) patients on belimumab therapy, and intra‐ and interindividual variations in plasma belimumab concentration were evaluated. A single‐center prospective study was conducted at Oita University Hospital to evaluate trough plasma concentrations over the course of treatment in 13 SLE patients treated with intravenous belimumab. Plasma belimumab concentrations were measured by a validated ultra‐high performance liquid chromatography with tandem mass spectrometry method. The median age of the patients was 40 (interquartile range: 35–51) years and the median weight was 51.8 (47.0–58.1) kg. A mean of 9.4 (range: 1–13) blood samples was collected per patient at routine visits. The mean (± SD) plasma belimumab concentration was 33.4 ± 11.9 μg/mL in the patient with the lowest concentration and 170.0 ± 16.6 μg/mL in the patient with the highest concentration, indicating a 5‐fold difference between patients. On the other hand, the within‐patient coefficient of variation ranged from 7.1% to 35.7%, showing no large variations. No significant correlation was observed between plasma belimumab concentration and belimumab dose (mg/kg) (Spearman's rank correlation coefficient = 0.22, p =.54). Examinations of trough plasma belimumab concentrations over the course of treatment in patients with SLE showed small intraindividual variation but large interindividual variation. Plasma belimumab trough concentration varied widely among patients administered the approved dose. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis.
- Author
-
Lu, Chaofan, He, Nan, Dou, Lei, Yu, Hongxia, Li, Mengtao, Leng, Xiaomei, and Zeng, Xiaofeng
- Subjects
- *
SYSTEMIC lupus erythematosus , *EARLY medical intervention , *PROPENSITY score matching , *BELIMUMAB , *DISEASE relapse , *LUPUS nephritis - Abstract
Objective: This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months. Methods: We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed. Results: Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low‐dose glucocorticoid (≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed. Conclusions: In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. 贝利尤单抗联合免疫抑制剂治疗诱发肺寄生虫感染1例.
- Author
-
黄妮娅, 周艳, and 马玲
- Abstract
Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
22. Real-world efficacy of belimumab in achieving remission or low-disease activity in systemic lupus erythematosus: A retrospective study.
- Author
-
Yasuhiro Hasegawa, Yoshiyuki Arinuma, Hirotomo Asakura, Risa Shindo, Kazuma Ino, Yoshiro Kanayama, Tomoki Tanaka, Yu Matsueda, Tatsuhiko Wada, Kenji Oku, and Kunihiro Yamaoka
- Subjects
- *
SYSTEMIC lupus erythematosus , *PROPORTIONAL hazards models , *PROPENSITY score matching , *DISEASE remission , *BELIMUMAB - Abstract
Objectives: We investigated the effect of belimumab (BEL) on achieving low disease activity (LDA) and remission as an additive molecular-targeting agent to standard of care (SoC) in patients with systemic lupus erythematosus (SLE). Methods: Clinical information was retrospectively collected from patients with SLE who received BEL additive to SoC (BEL + SoC), and from patients treated with SoC alone as a control arm. Disease activity was measured by SLE-disease activity score (SLE-DAS). The proportion of patients in LDA and remission at 12 months was compared after propensity score matching. The factors contributing to LDA and remission achievement were identified by Cox proportional hazard model. Results: BEL + SoC significantly reduced SLE-DAS at 6 months, with a significantly higher proportion of patients achieving LDA and remission at 12 months compared to SoC alone. The presence of arthritis at baseline was significantly associated with achieving LDA and remission. Additionally, both treatment groups experienced a significant reduction in daily glucocorticoid dose. Conclusions: Adding BEL to SoC was beneficial for patients with arthritis, leading to higher proportion of achieving LDA and remission, while also reducing their glucocorticoid dose. Our results indicate the utility of BEL in a treat-to-target approach for SLE patients in a real-world setting. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Nouvelles stratégies thérapeutiques dans le lupus érythémateux systémique d'après le congrès de l'EULAR 2023.
- Author
-
Carvajal Alegria, Guillermo and Felten, Renaud
- Subjects
- *
HYDROXYCHLOROQUINE , *CORTICOSTEROIDS , *IMMUNOSUPPRESSIVE agents , *SYSTEMIC lupus erythematosus , *BELIMUMAB - Abstract
Le congrès de l'EULAR 2023 a donné lieu à de nombreuses sessions autour du lupus érythémateux systémique (LES). L'objectif de cette mise au point est de discuter des nouvelles stratégies thérapeutiques dans cette maladie. Les recommandations pour la prise en charge thérapeutique du LES enfoncent le clou sur l'importance de l'hydroxychloroquine. Elles mettent clairement en avant l'effet délétère des corticoïdes au long cours et proposent une utilisation en relais permettant d'attendre l'effet d'un traitement de fond. Les traitements de fonds sont repositionnés en fonction des dernières données scientifiques et de nouvelles molécules, ayant obtenu une AMM, apparaissent comme l'anifrolumab ou la voclosporine. De potentiels nouveaux traitements ont été présentés dans les nombreuses sessions de résumés scientifiques. Le telitacept, une protéine de fusion ciblant BAFF et APRIL semble efficace en phase 2 (phase 3 en cours). L'elsubrutinib, un inhibiteur de la tyrosine kinase de Bruton a été évalué en association à l'upadacitinib. L'ianalumab, un anti-BAFF-récepteur a également montré des résultats intéressants en phase 2. Le baricitinib aurait une efficacité dans la néphrite lupique. Enfin, la thérapie par des lymphocytes T ayant un récepteur à l'antigène chimérique (CAR-T cells) ciblant les lymphocytes B (via le CD19) semble tenir ses promesses un an après la présentation des premières utilisations dans le LES. Par ailleurs, l'utilisation de la médecine personnalisée dans le LES a été débattue. Malgré des pistes prometteuses pour l'avenir, le choix d'un traitement reste aujourd'hui limité et uniquement guidé par la clinique et les éléments biologiques et histologiques « simples ». Numerous sessions about systemic lupus erythematosus (SLE) were scheduled during the EULAR2023 congress. The aim of this article is to discuss new therapeutic strategies in SLE based on the news from this congress. New recommendations for the treatment emphasize the importance of hydroxychloroquine, highlight clearly the deleterious effect of long-term corticosteroids, and suggest that they should be used as an adjunct to wait for the effect of a disease-modifying treatment. The various immunosuppressive and immunomodulatory drugs are repositioned in line with the latest scientific data. New molecules such as anifrolumab and voclosporin are introduced. Other molecules were also presented during the scientific abstract sessions such as telitacept (a fusion protein targeting BAFF and APRIL, effective in phase 2, with a phase 3 trial underway), elsubrutinib (a Bruton's tyrosine kinase inhibitor, evaluated in combination with upadacitinib) and ianalumab (an anti-BAFF-R antibody with encouraging results). An efficacy of baricitinib was surprisingly reported in lupus nephritis. Therapy with chimeric antigen receptor T cells (CAR-T cells) targeting B cells (via CD19) have still promising results a year after the first cases reported. Finally, the use of personalized medicine in SLE was debated. Despite promising avenues for the future, the choice of treatment today remains limited and only guided by "simple" clinical, biological and histological elements. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia.
- Author
-
Cheekati, Mahija and Murakhovskaya, Irina
- Subjects
IMMUNOLOGIC diseases ,PLASMA cells ,QUIESCENT plasmas ,IMMUNOREGULATION ,DISEASE management ,AUTOIMMUNE diseases ,AUTOIMMUNE hemolytic anemia - Abstract
Although rituximab is not specifically approved for the treatment of warm autoimmune hemolytic anemia (WAIHA), the First International Consensus Group recommends considering its use as part of the initial therapy for patients with severe disease and as a second-line therapy for primary WAIHA. Some patients do not respond to rituximab, and relapses are common. These relapses are associated with elevated B-cell-activating factor (BAFF) levels and the presence of quiescent long-lived plasma cells (LLPCs) in the spleen. A new group of immunomodulatory drugs, B-cell-activating factor inhibitors (BAFF-i), demonstrated efficacy in multiple autoimmune diseases and have the potential to improve WAIHA treatment outcomes by targeting B-cells and LLPCs. This article reviews the role of BAFF in autoimmune disorders and the currently available literature on the use of BAFF-directed therapies in various immunologic disorders, including WAIHA. Collectively, the clinical data thus far shows robust potential for targeting BAFF in WAIHA therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Effectiveness and safety of belimumab in Chinese adult lupus nephritis patients: a 24-week retrospective single-center real-world study
- Author
-
Pei-pei Jiang, Yuan-yuan Song, Han-qiu Yin, and Song-lou Yin
- Subjects
lupus nephritis ,belimumab ,real world ,efficacy evaluation ,Internal medicine ,RC31-1245 - Abstract
Objective To explore the effectiveness and safety of belimumab in Chinese adult lupus nephritis (LN) patients under a real-world setting. Methods For this retrospective cohort study, 30 LN patients received belimumab plus standard of care (SoC) due to a new onset or a relapse of LN from June 2021 to December 2022. And 30 matched patients only treated with SoC after propensity score matching (PSM) at the same period were also enrolled. After 24-week follow-ups, renal complete remission (CR), disease activity index, 24 h urine protein level, dose of prednisone and incidence of adverse events were compared. Results No statistically significant differences existed in baseline demographics, complement C3/C4, anti-dsDNA autoantibody titer, 24 h urine protein level or disease activity index. At Week 24, 21/30 patients achieved renal CR and it was higher than that of SoC group (21 vs 12, P=0.037). As compared with SoC group, belimumab group had lower levels of 24 h urine protein[346.50(183.75,571.00) mg vs 611.50(360.00,1450.00) mg], SLEDAI-2K (SLE disease activity index, SLEDAI-2K) score[(3.93±2.79) vs (5.70±3.14)] and daily prednisone dose [(11.67±4.34) mg/d vs (22.42±9.23) mg/d](P<0.05). Furthermore, the incidence of adverse events between two group was comparable (P>0.05). Conclusions Belimumab plus SoC may alleviate LN, boost the rate of renal CR, lower 24 h urine protein levels, improve disease activity and reduce the intake of prednisone.
- Published
- 2024
- Full Text
- View/download PDF
26. Immunobiological Therapies in Rheumatoid Arthritis: Mechanisms of Action and Future Perspectives
- Author
-
do Carmo, Nascar Katerine, de Lima, Isadora Soares, Miranda, Ana Júlia Machado, Viana, Camila Bariani Veloso, Borges, Leonardo Luiz, Cruvinel, Wilson de Melo, Taft, Carlton Anthony, Barreto da Silva, Vinícius, Gomes, Clayson Moura, Taft, Carlton A., editor, and de Almeida, Paulo Fernando, editor
- Published
- 2024
- Full Text
- View/download PDF
27. Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR)
- Author
-
GlaxoSmithKline
- Published
- 2023
28. Synergetic B-cell Immunomodulation in SLE - 2nd Study. (SynBioSe-2)
- Author
-
Dutch Kidney Foundation, GlaxoSmithKline, and Y.K.Onno Teng, Dr. Y.K.O. Teng, Nephrologist
- Published
- 2023
29. Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study
- Author
-
Bernard Rubin, Yan Chen, Karen Worley, Brendan Rabideau, Benson Wu, Rose Chang, and Maral DerSarkissian
- Subjects
Belimumab ,Early ,Healthcare resource utilization ,Immunosuppressant ,Systemic lupus erythematosus ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Introduction Patients with systemic lupus erythematosus (SLE) have variable treatment pathways, including antimalarials, glucocorticoids, immunosuppressants, and/or biologics. This study describes differences in clinical outcomes when initiating belimumab (BEL) before and after immunosuppressant use. Methods This real-world, retrospective cohort study (GSK Study 217536) used de-identified administrative claims data from January 2015 to December 2022 in the Komodo Health Database. Adults with moderate/severe SLE initiating BEL (index date) were identified from January 2017 to May 2022, allowing a ≥ 24-month baseline period. Patients were stratified into those initiating BEL before immunosuppressant use (no immunosuppressant use within 24 months before index) and those initiating BEL after immunosuppressant use (one immunosuppressant used within 24 months before index). Oral glucocorticoid (OGC) use, SLE flares, new organ damage, and all-cause healthcare resource utilization (HCRU) were analyzed descriptively over a 24-month follow-up. Results Baseline SLE severity was similar for patients initiating BEL before (n = 2295) versus after (n = 4114) immunosuppressant use (moderate, 83.1% vs 79.0%; severe, 16.8% vs 21.0%). Patients initiating BEL before versus after immunosuppressant use had lower SLE flare rates and OGC use. Post-index, patients initiating BEL before versus after immunosuppressant use discontinued their OGC sooner (moderate baseline SLE, 4.5 vs 8.9 months; severe baseline SLE, 6.2 vs 11.6 months). Patients initiating BEL before versus after immunosuppressant use had lower SLE flare rates per person-year at all time points (especially severe flare rates in patients with severe baseline SLE, 0.70 vs 1.48 through 24 months post-index). Median time to new organ damage occurrence was longer in patients initiating BEL before versus after immunosuppressant use (moderate baseline SLE, 32.1 vs 26.7 months; severe baseline SLE, 22.7 vs 21.6 months). All-cause HCRU was similar between cohorts. Conclusions These results suggest that patients initiating BEL before versus after immunosuppressant use had more favorable outcomes.
- Published
- 2024
- Full Text
- View/download PDF
30. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
- Author
-
Cuiling Fan, Tao Yang, Songyuan Zheng, Xiaozhong Liao, Ruixia Xie, Shixian Chen, and Juan Li
- Subjects
BELIMUMAB ,DISEASE progression ,LYMPHOCYTE count ,SCIENTIFIC observation ,SERUM albumin - Abstract
Objective: To collect real-world data regarding the attainment of the earlyachieved lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE) patients receiving telitacicept or belimumab treatment, and identify factors predictive of target achievement. Methods: Eighty-seven SLE patients who received telitacicept (N=42) or belimumab (N=45) were retrospectively reviewed in this observational study. Clinical and laboratory data, disease activity assessment, and glucocorticoid dosage were collected for analysis. Achieving LLDAS at least once within 24 weeks post-treatment was considered as early-achieved LLDAS. Multivariate regression was used to assess baseline predictive variables for early-achieved LLDAS. Subgroup analysis and interaction tests were also performed to examine the robustness of the results across different sets of baseline characteristics. Prognostic stratification for early-achieved LLDAS was established based on the identified risk factors. Results: During the 24-week follow-up period, LLDAS was achieved by at least one time in 49.43% (43/87) of the patients, with sustained achievement through week 24 observed in 36 out of these 43 patients (83.27%). Multivariate analysis revealed that early achievement of LLDAS was particularly observed in patients with higher baseline lymphocyte counts [HR=1.79, 95% CI (1.19-2.67), P=0.005] and serum albumin levels [HR=1.06, 95% CI (1.003-1.12), P=0.039]. Conversely, hematological involvement [HR=0.48, 95% CI (0.24-0.93), P=0.031] predicted lower attainment of early-achieved LLDAS. The use of telitacicept was associated with a reduced risk of failing to attain early achievement of LLDAS [HR=2.55, 95% CI (1.36-4.79), P=0.004]. Subgroup analyses and interaction tests showed a stable relationship between the telitacicept use and LLDAS achievement. The results remained consistent across all subgroup analyses. Significant differences (P<0.001) were observed in the Kaplan-Meier estimates for LLDAS among risk groups based on the number of identified risk factors. Conclusion: The achievement of LLDAS is attainable in the management of SLE patients undergoing treatment with telitacicept or belimumab in real-life clinical practice. Baseline lymphocyte counts, serum albumin levels, hematological involvement and the use of telitacicept serve as robust predictors for earlyachieved LLDAS, helping to identify patients who are likely to benefit on the treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Considering belimumab during pregnancy: A more viable option over time.
- Author
-
Vela-Casasempere, Paloma, Caño Alameda, Rocío, Gómez Sabater, Silvia, Cortell Aznar, Silvia, and Pérez Pascual, Encarnación
- Subjects
- *
PREGNANT women , *ECTOPIC pregnancy , *BELIMUMAB , *MISCARRIAGE , *GESTATIONAL diabetes , *FETAL growth retardation - Abstract
Objective: To share our experience with belimumab in lupus pregnant women and to review the relevant published literature on its use in this scenario. Methods: A prospective observational study of pregnant patients with lupus was conducted. Additionally, MEDLINE and EMBASE databases were searched, and a secondary hand search of the literature was performed. Studies were evaluated and visualised descriptively. Results: Sixteen pregnancies of 12 lupus women were included, six (involving eight pregnancies) received belimumab throughout their illness, five of them during some period of gestation. In this group, there was one miscarriage, one elective termination and seven live foetuses (including two live twins). There was one type I intrauterine growth retardation, and a preterm pregnancy due to premature rupture of membranes (PPROM). One mild lupus flare was detected. There were no cases of pre-eclampsia, gestational diabetes mellitus or hypertension. All neonates had normal Apgar scores at birth, none needed critical care. There were no congenital anomalies. After the search, we identified 10 case reports and case series, and five registries. Among the 39 reported cases (41 pregnancies), there were 5 PPROM, 4 pre-eclampsia, and 1 eclampsia. All women made full recoveries. Nineteen new-borns had low birth weight. There were no malformations. While registries did not indicate an increased risk of birth defects or pregnancy loss, there was a higher risk of neonatal infections. Conclusions: Belimumab may be an option for pregnant women with difficult-to-control lupus. Further research is needed to confirm the absence of association between belimumab and foetal harm. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Early effectiveness and safety analysis of belimumab in addition to standard treatment in patients with systemic lupus erythematosus.
- Author
-
Lingyan He, Mingming Yan, Rui Wen, and Jiali Li
- Subjects
- *
COMBINATION drug therapy , *PATIENT safety , *DRUG side effects , *SYSTEMIC lupus erythematosus , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DNA , *DESCRIPTIVE statistics , *PREDNISONE , *SYMPTOMS , *SEVERITY of illness index , *MONOCLONAL antibodies , *BELIMUMAB , *DRUG efficacy , *TIME , *BIOMARKERS - Abstract
Objectives: This study aimed to evaluate the early effectiveness and safety of belimumab in addition to standard therapy in patients with systemic lupus erythematosus (SLE) for 24 weeks. Patients and methods: This retrospective study was conducted with 60 adult patients with active SLE between June 2020 and August 2022. The patients either received intravenous belimumab in addition to standard therapy (n=31; 24 females, 7 males; mean age: 33.7±14.1 years; range, 18 to 52 years) or only standard therapy (n=29; 22 females, 7 males; mean age: 34.1±13.4 years; range, 19 to 66 years) for 24 weeks. Outcome measures, including safety and effectiveness (Safety of Estrogens in Lupus Erythematosus National Assessment--Systemic Lupus Erythematosus Disease Activity Index [SELENA-SLEDAI]), changes in biomarkers (double-stranded DNA [deoxyribonucleic acid]), serum complement levels, and immunoglobin G (IgG) were recorded. Adverse events were recorded. Results: Baseline demographic and clinical characteristics were similar between the two groups. More patients in the belimumab group achieved a reduction of ≥4 points in SELENA-SLEDAI at weeks 12 and 24 (week 12, 77.4% vs. 41.4%, p=0.008; week 24, 87.1% vs. 48.3%, p=0.002). The mean score of SELENA-SLEDAI was significantly lower in the belimumab group compared to the standard therapy group at week 12. However, a significant difference was not reached at week 24. Moreover, mean levels of serum C3 and C4 in the belimumab group were significantly higher than those in the standard therapy group at weeks 12 and 24. A higher proportion of patients in the belimumab group had a normal C3 level than in the standard therapy group. In addition, belimumab treatment resulted in a significant decrease in IgG levels at both weeks 12 and 24. At week 24, the belimumab group had a higher reduction in prednisone dose than the standard therapy group. Furthermore, the percentages of patients with more than 50% reduction in prednisone over baseline were significantly greater for belimumab versus standard therapy at week 12 (p=0.002). The occurrence of adverse events was similar between the two groups (standard therapy group, 44.8%; belimumab group, 51.6%). Conclusion: Intravenous belimumab was well tolerated and significantly improved disease activity in Chinese patients with SLE at the early stage of treatment. More importantly, belimumab treatment could result in a rapid reduction in prednisone dose as early as week 12. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. COVID-19 in Systemic Lupus Erythematosus patients treated with belimumab: a retrospective clinical study.
- Author
-
Wu, Yinlan, Li, Yanhong, Wu, Tong, Huang, Deying, Wu, Jianhong, Zhang, Weihua, Jiang, Xuejun, Yao, Chaoqiong, Liang, Xiuping, Cheng, Lu, Liao, Zehui, Xu, Fang, Tan, Chunyu, Liu, Yi, and Herrmann, Martin
- Abstract
Background: Routine use of immunosuppressive agents in systemic lupus erythematosus (SLE) patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potentially increases the risk of adverse outcomes. belimumab, a monoclonal antibody for the treatment of SLE, remains untested for its specific impact on coronavirus disease 2019 (COVID-19) symptoms in these patients. Here, this research investigated the effect of belimumab on COVID-19 symptoms in SLE patients infected with SARS-CoV-2. Methods: This study enrolled SLE patients who underwent treatment with belimumab. After thorough screening based on the inclusion and exclusion criteria, data pertaining to COVID-19 for both the participants and their cohabitants were obtained through telephone follow-up. The potential impact of belimumab on COVID-19 was evaluated by comparing COVID-19 symptoms and medication use across various groups to investigate the association between belimumab treatment and COVID-19 in SLE. Results: This study involved 123 SLE patients, of whom 89.4% tested positive for SARS-CoV-2. Among cohabitants of SLE patients, the SARS-CoV-2 positive rate was 87.2% (p = 0.543). Patients treated with belimumab exhibited a lower incidence of multiple COVID-19 symptoms than their cohabitating counterparts (p < 0.001). This protective effect was found to be partially related to the time of last belimumab administration. Among those with COVID-19, 30 patients opted to discontinue their anti-SLE drugs, and among them, 53% chose to discontinue belimumab. Discontinuing drugs did not increase the risk of hospitalization due to SARS-CoV-2 infection. Conclusion: This study concluded that treatment with belimumab did not increase susceptibility to COVID-19 and beneficially alleviated the symptoms of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab: A case series.
- Author
-
Fan, Qiuyu, Yang, Huiqin, and Liu, Ya
- Abstract
Copyright of Zeitschrift für Rheumatologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
35. The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study.
- Author
-
Wu, Qi, Zhao, Ming-Xue, Huang, Xiao-Shan, Lin, Chang-song, and Xu, Qiang
- Abstract
Objective: The objective of this study is to provide a description of a group of retrospective cohort outcomes in patients with systemic lupus erythematosus (SLE) complicated with immune thrombocytopenia (ITP) receiving belimumab. Methods: This study reports on the treatment of 10 female patients (mean age 34.3 ± 14.0 years, mean weight 58.7 ± 18.2 kg) with both SLE and ITP who received belimumab in addition to basic drug therapy. The belimumab treatment regimen consisted of a dosage of 10 mg/kg, with an initial infusion every 2 weeks for the first 3 doses, followed by an infusion every 4 weeks. Results: Ten patients were included in the study. The overall response rate of thrombocytopenia was 90% after treatment. The parameters such as platelet count, lymphocyte count, erythrocyte count, hemoglobin, dsDNA, C3, and C4 were significantly improved (p <.05). The SLE Disease Activity Index (SLEDAI), British Islet lupus Assessment Group 2004 (BILAG-2004), and Physician Global assessment (PGA) scores were significantly decreased (p <.05). There were no significant differences in glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), and serum creatinine (Scr) before and after treatment (p >.05). Conclusion: Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP. Further studies are needed to validate these findings in larger patient populations and compare the efficacy of belimumab with other treatments for SLE complicated with ITP. Long-term response rates and adverse events associated with belimumab treatment also warrant further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Initiation of belimumab with higher daily prednisolone is effective for rapid glucocorticoid reduction: A 96-week retrospective study.
- Author
-
Yamane, Takashi and Hashiramoto, Akira
- Abstract
Objectives: For appropriate glucocorticoid (GC) reduction, we investigated the optimal strategy including baseline factors that could reduce GC more than 50% with 96 weeks of belimumab. Methods: This is a retrospective cohort study of Kakogawa Central City hospital from 2019 to 2023. We identified SLE patients who were receiving 200 mg of belimumab weekly by subcutaneous injection for 96 weeks. The background at baseline, trends in clinical indicators, and factors involved in GC reduction were statistically analyzed. Finally, univariate and multivariate logistic analyses were carried out to identify baseline factors associated ≥50% GC reduction at 96 weeks. Results: Forty-seven patients were enrolled, with a median daily prednisolone of 5 mg. Almost 90% of them received concomitant immunosuppressants and/or hydroxychloroquine. Serological indices, daily GC dose, and SLEDAI-2K scores showed significant improvement in 96 weeks. At baseline, a significant negative correlation has been shown between the daily dose of GC and the duration from onset or last flare, as well as C4 levels. At 96 weeks, GC reduction rate and SLEDAI-2K scores were negatively correlated with duration from onset or last flare to initiation of belimumab. Mycophenolate mofetil use was significantly frequent in patients with lupus nephritis (LN), which also correlated with the frequency of past flares. In addition, LN presence was associated with higher SLEDAI-2K scores at 96 weeks, and baseline SLEDAI-2K ≥10 was associated with significantly higher GC dose at 96 weeks. Univariate analysis of the factor contributing to achieving ≥50% GC reduction at 96 weeks has pointed shorter disease duration and higher daily GC dose at baseline as significant variables. Finally, we performed a multivariate analysis by combining above two items with age, which extracted the higher daily GC dose at baseline as a significant variable (OR (95% CI) 1.25 (1.00 to 1.56), p =.047). Conclusions: Our study showed that a delay in belimumab initiation led to higher SLEDAI-2K score and difficulty in achieving a 50% GC reduction at 96 weeks. Since GC-related adverse events increase with long-term administration of GC though with small daily doses, we proposed here that belimumab should be started in combination with higher daily prednisolone. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
- Author
-
Wang, Li, Liang, Xiaohua, Cao, Zhilang, Wang, Dahai, Luo, Ying, Feng, Yuan, Luo, Chong, Zhi, Shufeng, Huang, Yiling, Fan, Zhidan, Wang, Chaoying, Liu, Haimei, Liu, Jinxiang, Zhang, Tianyu, Cheng, Qiuting, Xie, Xue, Shuai, Lanjun, Rong, Zanhua, Zeng, Ping, and Yu, Haiguo
- Subjects
- *
STEROID drugs , *POISSON distribution , *PATIENT safety , *RESEARCH funding , *MULTIPLE regression analysis , *SYSTEMIC lupus erythematosus , *DISEASE remission , *PATIENT care , *CHILDREN'S hospitals , *BELIMUMAB , *LONGITUDINAL method , *PRE-tests & post-tests , *DRUG efficacy , *RESEARCH , *DISEASE progression , *EVALUATION , *CHILDREN - Abstract
Objective The aim of this study is to identify whether low lupus disease activity status (LLDAS) and clinical remission (CR) of belimumab plus standard of care (SoC) therapy are achievable goals in childhood-onset SLE (cSLE). Methods This multicentre, one arm pre-post intervention study was conducted at 15 centres in China. The primary end point was to describe the proportion of patients who achieved LLDAS and CR after 3, 6 and 12 months after treatment with belimumab plus SoC therapy. A multiple regression model was used to impute missing data. A Poisson regression model was used to calculate the effect of belimumab treatment on the reduced risk of serious diseases and the incidence of new damage. Result A total of 193 (92.2% female) with active cSLE from 15 centres were included. At 3, 6 and 12 months, the proportion of LLDAS (CR) was 12.4% (1.0%), 25.6% (4.5%) and 70.3% (29.7%), respectively. The mean SELENA-SLEDAI score decreased from 11.0 at baseline to 3.7, 2.9 and 1.7 at 3, 6 and 12 months. At baseline, all patients received steroids at a mean (s. d.) prednisone equivalent dose of 31.0 (18.2) mg/day, which decreased to 19.4 (10.8) mg/day at month 3, 12.6 (7.2) mg/day at month 6 and 6.7 (5.3) mg/day at month 12. The symptoms and immunological indicators were also significantly improved. Conclusion This is the first and largest sample size prospective clinical intervention study of cSLE patients treated with belimumab in China. LLDAS and CR were attainable treat-to-target of belimumab plus SoC therapy in cSLE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Glucocorticoid-free remission in patients with SLE in the era of biologics: Immune complex disease is likely to benefit from current medications.
- Author
-
Oiwa, Hiroshi, Suga, Takeshi, Hosokawa, Yohei, and Araki, Kei
- Subjects
- *
IMMUNE complexes , *BIOLOGICALS , *IMMUNOSUPPRESSIVE agents , *DRUGS , *DISEASE remission , *ISCHEMIC colitis - Abstract
Objectives: In addition to various immunosuppressive agents, belimumab and anifrolumab became available in Japan. We aimed to investigate glucocorticoid-free clinical remission in a single-centre retrospective cohort in October 2023. Methods: Our cohort included patients with SLE who needed to start or increase glucocorticoids for disease activity and were followed up for more than 1 year. We investigated the rate of achievement of clinical remission off corticosteroids (CR off C), defined as no clinical score on the SLEDAI-2K without glucocorticoids, baseline predictors of CR off C, medications used when CR off C was achieved, and flare rates following CR off C. Results: Out of the 60 patients followed for an average of 5.4 (±2.6) years, 17 (28.3%) achieved CR off C in 3.6 (±1.2) years after enrolment. Use of belimumab and anifrolumab accounted for eight (47.1%) of the achievers. Among the baseline data, male sex, recent enrolment, high glucocorticoid dose, and detection of immune complex (IC) significantly predicted CR off C, while lupus nephritis (LN) and a low C3 level tended to predict it. In the multivariate analysis, IC detection was the only predictor of CR off C. Clinical flares were observed in 5.9% of the achievers during a median 1.2 years after achievement of CR off C. Conclusion: In the era of biologics, CR off C was achieved in 28.3% of the patient cohort requiring the start or increase of glucocorticoids for disease activity, with a relatively low rate of flares, suggesting that glucocorticoid-free clinical remission is an achievable target in SLE. IC disease, represented by male sex or nephritis, is likely to benefit from currently available medications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice.
- Author
-
Frade-Sosa, Beatriz, Salman-Monte, Tarek Carlos, Narváez, Javier, Peralta, Irene, Sandoval, Sebastian, Magallares, Berta, Heredia, Sergi, Sapena, Nuria, Riveros-Frutos, Anne, Olivé, Alejandro, Corominas, Hector, Cortés-Hernández, Josefina, and Gómez-Puerta, José A
- Subjects
- *
SATISFACTION , *PATIENT satisfaction , *BELIMUMAB - Abstract
Background: In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction. Methods: Observational, multicenter study, conducted in 7 reference centers in Catalonia. We included stable SLE patients (EULAR/ACR 2019) on treatment with SQ BEL and previous use of IV BEL (at least 3 months on IV BEL before switching). Since there are no well-validated tools for SQ BEL treatment satisfaction, we used RASQ-SQ, validated in patients with lymphoma who switched from IV Rituximab to SQ treatment, and modified for BEL treatment. Results: Twenty-seven patients were included. The more prevalent clinical manifestations observed were related to the skin and joints and the patients had a mean baseline SLEDAI of 2.96 (SD 2.4) and SLICC score of 0.67 (SD 0.88). The median time from treatment with IV BEL before switching to SQ was 21 months (range). 84% of patients reported confidence in SQ BEL. 85.2% felt that treatment with SQ BEL was convenient or very convenient. 85% felt they had gained time with the change. 89% would recommend the SQ injection to other patients. Disease activity (mean SLEDAI) and remission rates remain stable after switching. No major new adverse effects were reported. Conclusions: Overall satisfaction, satisfaction with via of administration, and satisfaction with the time taken to receive BEL were higher for SQ BEL treatment. A switching SQ strategy is a reasonable alternative for BEL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Blockade of BLyS inhibits B-cell responses and antibody production for the prevention of chronic transplant rejection.
- Author
-
Liao, Tao, Shi, Xiaoyi, Han, Fei, Wang, Yuchen, Zeng, Wenli, Liu, Rumin, Yan, Ziyan, Xia, Renfei, Huang, Zhengyu, Xu, Jian, and Miao, Yun
- Subjects
- *
ANTIBODY formation , *GRAFT rejection , *BONE marrow , *PLASMA cells , *B cells , *TALL-1 (Protein) - Abstract
Chronic rejection, closely related to the activation of B cells and donor-specific antibody (DSA) production, has unsatisfactory therapeutic outcomes. B lymphocyte stimulator (BLyS) is a major regulatory factor that controls the activation and differentiation of B cells. However, it remains unclear whether BLyS blockade can regulate B and plasma cells in the transplantation setting and affect chronic rejection. Here, we investigated the efficacy of the BLyS inhibitors belimumab and telitacicept in controlling B-cell response and preventing chronic rejection. The effects of belimumab and telitacicept on B-cell activation, differentiation, and antibody production in vitro were determined. A chronic rejection model in mouse was established by allogeneic cardiac transplantation with CTLA4-Ig treatment. Allograft survival, histology, DSA levels, and B-cell responses were analyzed to evaluate the chronic rejection-preventive effects of belimumab and telitacicept. In vitro experiments confirmed that belimumab and telitacicept inhibited B-cell activation and differentiation and reduced antibody production. In vivo experiments indicated that they significantly prolonged allograft survival, attenuated chronic rejection through significant suppression of myocardial ischemic necrosis and interstitial fibrosis, and reduced DSA-IgG levels, C4d deposition, and inflammatory cell infiltration. Furthermore, the frequencies of B cells, plasma cells, and IgG-producing cells in the recipients' spleen, lymph nodes, bone marrow, and blood were decreased after BLyS inhibitors treatment. This study demonstrated that belimumab and telitacicept inhibit B-cell responses and antibody production and alleviate chronic transplant rejection. Therefore, BLyS inhibitors are expected to be used for the prevention of chronic rejection in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
- Author
-
Fan, Qiuyu, Ji, Hongyan, Liu, Ya, Jia, Chao, Zou, Liang, and Yang, Huiqin
- Subjects
- *
LITERATURE reviews , *TALL-1 (Protein) , *TREATMENT effectiveness , *BELIMUMAB , *HEPATITIS , *LUPUS nephritis - Abstract
Background: Systemic lupus erythematosus (SLE)–associated hepatitis ("lupus hepatitis") was one of the most frequent causes of liver function abnormalities in patients with SLE. Lupus hepatitis (LH) is commonly treated with conventional treatment, including non-steroidal anti-inflammatory drugs, corticosteroids, and immunomodulators. However, in refractory cases, other treatment options may be required. Methodology: We report the case of a patient with lupus hepatitis refractory to both conventional therapy and belimumab who was successfully treated with telitacicept, a new dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor.Literature review was performed on PubMed search forum. Result: The specific search term was "telitacicept", 23 papers were searched, among them 10 case reports/series articles reporting telitacicept treatment were elected.Apart from our literature reporting the effectiveness of telitacicept in treating LH, there is no report on it in treating LH. Conclusion: This case suggests that telitacicept should be an effective and safe treatment for LH refractory, even to those who failed to belimumab based on the standard treatment, and can reduce the dosage of glucocorticoids.However, further investigations, particularly prospective randomized controlled trials, are warranted to verify our findings and ensure patient safety. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Biologische Therapie bei systemischem Lupus erythematodes, Antiphospholipid-Syndrom und Sjögren-Syndrom: evidenz- und praxisbasierte Leitlinien.
- Author
-
Marinho, António, Alves, José Delgado, Fortuna, Jorge, Faria, Raquel, Almeida, Isabel, Alves, Glória, Correia, João Araújo, Campar, Ana, Brandão, Mariana, Crespo, Jorge, Marado, Daniela, Matos-Costa, João, Oliveira, Susana, Salvador, Fernando, Santos, Lelita, Silva, Fátima, Fernandes, Milene, and Vasconcelos, Carlos
- Subjects
- *
ECULIZUMAB , *PRAXIS (Process) , *BARICITINIB , *BORTEZOMIB , *BELIMUMAB - Abstract
Zusammenfassung: Systemischer Lupus erythematodes (SLE), das Antiphospholipid-Syndrom (APS) und das Sjögren-Syndrom (SS) sind heterogene Autoimmunerkrankungen. Schwere Ausprägungen sowie Therapieresistenz bzw. -unverträglichkeit gegenüber herkömmlichen Immunsuppressiva erfordern andere Behandlungsoptionen, d.h. biologische Arzneimittel und kleine Moleküle. Unser Ziel war es, evidenz- und praxisbasierte Leitlinien für die zulassungsüberschreitende Anwendung von Biologika bei SLE, APS und SS zu definieren. Die Empfehlungen wurden nach einem umfassenden Literaturreview und 2 Konsensrunden durch ein unabhängiges Expertengremium abgegeben. Das Gremium umfasste 17 Experten für Innere Medizin mit anerkannter Praxis im Bereich der Behandlung von Autoimmunerkrankungen. Die Literaturrecherche erfolgte systematisch für die Jahre von 2014 bis 2019 und wurde später durch Querverweisprüfungen und Experteninformationen bis 2021 aktualisiert. Es wurden vorläufige Empfehlungen von Arbeitsgruppen für jede Krankheit erarbeitet. Ein Revisionsmeeting mit allen Experten fand vor dem Konsensmeeting im Juni 2021 statt. Alle Experten stimmten in 2 Runden ab (stimme zu, stimme nicht zu, stimme weder zu noch widerspreche ich), und Empfehlungen mit mindestens 75% Zustimmung wurden anerkannt. Insgesamt 32 abschließende Empfehlungen (20 für die SLE-, 5 für die APS- und 7 für die SS-Behandlung) wurden von den Experten anerkannt. Diese Empfehlungen berücksichtigen die Organbeteiligung, die Ausprägung, den Schweregrad und das Ansprechen auf frühere Behandlungen. Bei diesen 3 Autoimmunkrankheiten beziehen sich die meisten Empfehlungen auf Rituximab, was auf die höhere Anzahl von Studien und der klinischen Erfahrung mit diesem biologischen Wirkstoff zurückzuführen ist. Eine sequenzielle Behandlung mit Belimumab nach Rituximab kann auch bei schweren Fällen von SLE und SS indiziert sein. Eine Zweitlinientherapie mit Baricitinib, Bortezomib, Eculizumab, Secukinumab oder Tocilizumab kann bei SLE-spezifischen Ausprägungen erwogen werden. Diese evidenz- und praxisbasierten Empfehlungen können die Behandlungsentscheidung unterstützen und letztendlich das Behandlungsergebnis bei Patienten mit SLE, APS oder SS verbessern. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis
- Author
-
Chaofan Lu, Nan He, Lei Dou, Hongxia Yu, Mengtao Li, Xiaomei Leng, and Xiaofeng Zeng
- Subjects
belimumab ,early medical intervention ,LLDAS ,lupus nephritis ,systemic lupus erythematosus ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Objective This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months. Methods We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed. Results Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low‐dose glucocorticoid ( ≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed. Conclusions In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision.
- Published
- 2024
- Full Text
- View/download PDF
44. Evaluation of intra‐ and inter‐individual variations in plasma belimumab concentrations in adult patients with systemic lupus erythematosus
- Author
-
Chisato Yoshijima, Yosuke Suzuki, Ryota Tanaka, Hiroyuki Ono, Ayako Oda, Takashi Ozaki, Hirotaka Shibata, Hiroki Itoh, and Keiko Ohno
- Subjects
belimumab ,pharmacokinetics ,systemic lupus erythematosus ,therapeutic drug monitoring ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract In this study, plasma belimumab concentrations were measured over the course of treatment in systemic lupus erythematosus (SLE) patients on belimumab therapy, and intra‐ and interindividual variations in plasma belimumab concentration were evaluated. A single‐center prospective study was conducted at Oita University Hospital to evaluate trough plasma concentrations over the course of treatment in 13 SLE patients treated with intravenous belimumab. Plasma belimumab concentrations were measured by a validated ultra‐high performance liquid chromatography with tandem mass spectrometry method. The median age of the patients was 40 (interquartile range: 35–51) years and the median weight was 51.8 (47.0–58.1) kg. A mean of 9.4 (range: 1–13) blood samples was collected per patient at routine visits. The mean (± SD) plasma belimumab concentration was 33.4 ± 11.9 μg/mL in the patient with the lowest concentration and 170.0 ± 16.6 μg/mL in the patient with the highest concentration, indicating a 5‐fold difference between patients. On the other hand, the within‐patient coefficient of variation ranged from 7.1% to 35.7%, showing no large variations. No significant correlation was observed between plasma belimumab concentration and belimumab dose (mg/kg) (Spearman's rank correlation coefficient = 0.22, p = .54). Examinations of trough plasma belimumab concentrations over the course of treatment in patients with SLE showed small intraindividual variation but large interindividual variation. Plasma belimumab trough concentration varied widely among patients administered the approved dose.
- Published
- 2024
- Full Text
- View/download PDF
45. Successful treatment of lupus protein-losing enteropathy with belimumab: A case report.
- Author
-
Marenori Kojima, Hironari Hanaoka, Kaito Aoki, Hiromi Matsushita, Hiroshi Ito, and Hidehiro Yamada
- Subjects
- *
PROTEIN-losing enteropathy , *SYSTEMIC lupus erythematosus , *SJOGREN'S syndrome , *INFORMED consent (Medical law) , *SERUM albumin - Abstract
This article, published in Modern Rheumatology Case Reports, discusses the successful treatment of lupus protein-losing enteropathy (LUPLE) with belimumab. LUPLE is a rare condition in patients with systemic lupus erythematosus (SLE) that causes oedema and other symptoms due to hypoalbuminemia. The exact causes and treatment of LUPLE are not well understood, but this case report suggests that belimumab monotherapy may be an effective treatment option. Belimumab is a medication that suppresses B-cell activation and has been shown to normalize low complement levels and reduce autoantibodies in SLE patients. Further studies are needed to confirm the effectiveness of belimumab for LUPLE. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
46. Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus.
- Author
-
Tull, Thomas J, Benton, Emma C, Semkova, Kristina, Watson, Natalie A, Mee, John B, Lopez, Begona, Setterfield, Jane, Carey, Barbara, Ahmad, Sajjad, Robbie, Scott J, Groves, Richard W, Sanna, Giovanni, and D'Cruz, David P
- Subjects
- *
SYSTEMIC lupus erythematosus , *EPIDERMOLYSIS bullosa , *BELIMUMAB , *RITUXIMAB , *TALL-1 (Protein) , *RAYNAUD'S disease - Abstract
This article discusses the use of combined rituximab and belimumab therapy to treat recalcitrant epidermolysis bullosa aquisita (EBA) associated with systemic lupus erythematosus (SLE). EBA is a rare blistering disorder caused by antibodies that bind to type VII collagen, resulting in blister formation. The two patients in the study had severe skin fragility and laryngopharyngeal ulceration, and previous treatments had failed to control the disease. Treatment with rituximab and belimumab resulted in complete B-cell depletion and a decrease in anti-collagen VII antibody titres, leading to a dramatic improvement in cutaneous lesions. The authors suggest that this combined therapy may be a safe and effective treatment for recalcitrant EBA and other immunobullous disorders. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
47. A Model About the Response of Belimumab in SLE (MRBS)
- Published
- 2023
48. Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia (RITUX-PLUS 2)
- Author
-
GlaxoSmithKline
- Published
- 2023
49. Belimumab Assessment of Safety in SLE (BASE)
- Published
- 2023
50. Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies (BOTEGA)
- Author
-
GlaxoSmithKline and Mark Dransfield, MD, Principal Investigator
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.